๐ ็ธฝ็ฎ้ ๏ฝ ๐ ่ฑๆๅๆ๏ผๆฌ็ฏ๏ผ ๏ฝ ๐ ๅฎๆด็ฟป่ญฏ ๏ฝ โญ ็ฒพ่ฏ็ญ่จ
Introduction
Jennifer T. Huang and Edward W. Cowen Graft-versus-Host Disease 52
Key features
ยCurrently, over 35โ000 allogeneic hematopoietic stem cell trans- plants (HSCTs) are performed worldwide each year
ยAn HLA-matched sibling donor is the ideal donor source
ยNowadays nearly all eligible patients can receive an allogeneic
HSCT due to the increased use of alternative stem cell sources including matched unrelated donors, haploidentical donors, and umbilical cord blood
ยReduced intensity conditioning regimens allow older patients and those with comorbidities to receive allogeneic HSCTs
ยDonor lymphocyte infusions as well as withdrawal of immunosup- pression may impact the incidence, timing, and presentation of graft-versus-host disease (GVHD)
ยAcute GVHD is a major complication of allogeneic HSCT; severe skin involvement, although uncommon, is associated with a high mortality rate
ยChronic cutaneous GVHD is a polymorphous condition with features that can resemble lichen planus, lichen sclerosus, morphea, and eosinophilic fasciitis
ยChronic cutaneous GVHD is difficult to treat and the aggressiveness of treatment must be balanced against the complications of chronic immunosuppression